^
    2d
    A Phase III Clinical Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P3, N=394, Recruiting, Guangzhou Lupeng Pharmaceutical Company LTD.
    New P3 trial
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Inokai (orelabrutinib) • rocbrutinib (LP-168)
    3d
    An Open-Label, Single-Arm Study of Sonrotoclax Plus Zanubrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without Disease Progression After First-Line BTK Inhibitor Therapy. (ChiCTR2500111878)
    P=N/A, N=50, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New trial
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    3d
    A prospective, single-arm, multicenter clinical study of zanubrutinib in combination with obinutuzumab and low-dose bendamustine as first-line treatment for high-risk (FLIPI-2 >= 3) follicular lymphoma patients. (ChiCTR2500114118)
    P4, N=25, Not yet recruiting, People‘s Hospital of Xinjiang Uygur Autonomous Region; People‘s Hospital of Xinjiang Uygur Autonomous Region
    New P4 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • bendamustine
    3d
    Zanubrutinib Combined with Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in Treatment-Naive Waldenström's Macroglobulinemia: A Phase II Clinical Study (ChiCTR2500113199)
    P2, N=43, Not yet recruiting, Institute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Hematology Hospital); Institute of Hematology, Chine
    New P2 trial
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • bendamustine
    3d
    Immuno and targeted therapy for Richter transformation to diffuse large B-cell lymphoma (ChiCTR2500109894)
    P2, N=34, Not yet recruiting, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • PD-1 (Programmed cell death 1)
    |
    CD20 positive
    |
    lenalidomide • Tevimbra (tislelizumab-jsgr) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Columvi (glofitamab-gxbm)
    5d
    Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=50, Recruiting, Beijing Tongren Hospital
    New P2 trial
    |
    CD5 (CD5 Molecule)
    |
    doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • Polivy (polatuzumab vedotin-piiq)
    6d
    BGB-3111-215t: Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment (clinicaltrials.gov)
    P2, N=96, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib)
    6d
    BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders. (PubMed, Biomolecules)
    Covalent BTK inhibitors (ibrutinib, acalabrutinib, and zanubrutinib) irreversibly bind the C481 residue and have produced high response rates and durable disease control, often replacing chemoimmunotherapy in the relapsed setting and, for some entities, even in the first line. Non-covalent BTK inhibitors (e.g., pirtobrutinib) bind BTK independently of C481, can overcome classic C481-mediated resistance, and extend BTK pathway targeting into later lines of therapy. Overall, BTK inhibition has evolved into a versatile platform enabling long-term, often chemo-free management strategies.
    Review • Journal • IO biomarker
    |
    PLCG2 (Phospholipase C Gamma 2)
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Jaypirca (pirtobrutinib)
    7d
    PRT2527-02: A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies (clinicaltrials.gov)
    P1, N=86, Completed, Prelude Therapeutics | Active, not recruiting --> Completed
    Trial completion
    |
    Venclexta (venetoclax) • Brukinsa (zanubrutinib) • PRT2527
    8d
    An Indirect Comparison of Zanubrutinib vs Acalabrutinib Plus Venetoclax in Patients With Treatment-Naive CLL. (PubMed, Blood Adv)
    In the phase 3 randomized SEQUOIA study (NCT03336333), zanubrutinib (arm A) demonstrated superior progression-free survival (PFS) compared with bendamustine-rituximab (BR; arm B) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) without del(17p). In the phase 3 AMPLIFY study (NCT03836261), acalabrutinib-venetoclax with or without obinutuzumab demonstrated prolonged PFS vs chemoimmunotherapy (investigator's choice of fludarabine, cyclophosphamide, and rituximab [FCR] or BR) in patients with treatment-naive CLL without del(17p) or TP53 mutations...Zanubrutinib also demonstrated longer PFS whether adjusted for age (PFS-INV hazard ratio &lsqb;HR], 0.26; 95% CI, 0.13-0.54; P<.0003) or unadjusted (PFS-INV HR, 0.45; 95% CI, 0.23-0.88; P=.0197). These results highlight zanubrutinib monotherapy as an effective treatment option for all patients with treatment-naive CLL/SLL, including patients who might otherwise be considered for more intensive fixed-duration combination regimens.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 mutation + Chr del(17p)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Gazyva (obinutuzumab) • cyclophosphamide • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • bendamustine • fludarabine IV
    18d
    RITZ: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients (clinicaltrials.gov)
    P3, N=122, Active, not recruiting, International Extranodal Lymphoma Study Group (IELSG) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • MME (Membrane Metalloendopeptidase) • ITGAE (Integrin Subunit Alpha E)
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • Truxima (rituximab-abbs)
    19d
    Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Canadian Cancer Trials Group
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)